Merck & Co., Inc. vs Pfizer Inc.: Strategic Comparison

This in-depth comparison examines Merck & Co., Inc. and Pfizer Inc. across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Merck & Co., Inc. on its own, evaluating Pfizer Inc., or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Merck & Co., Inc. and Pfizer Inc. is widest.

On the headline numbers, annual revenue is $65.0B (FY2025) for Merck & Co., Inc. and $62.6B (FY2025) for Pfizer Inc., while their respective market capitalizations stand at $368.3B and $160.3B. Both Merck & Co., Inc. and Pfizer Inc. are headquartered in United States. Their local markets and applicable rules may still differ.

Merck & Co., Inc.: Merck & Co. is one of the largest U.S. pharmaceutical companies by sales, with $65.0 billion in 2025 revenue, about 75,000 employees and a market value near $368 billion in late September 2026. It researches, makes and sells cancer drugs, vaccines, cardiovascular and infectious-disease medicines, and animal health products in more than 140 markets. Keytruda, its PD-1 cancer immunotherapy, was the world's top-selling drug brand in 2025 and drives about half of company sales, so the company's current agenda centers on replacing that revenue before U.S. patent protection begins to lapse in 2028. The company is headquartered in Rahway, New Jersey.

Pfizer Inc.: Pfizer Inc. (NYSE: PFE) is one of the largest pharmaceutical companies in the world by revenue, headquartered at The Spiral, 66 Hudson Boulevard East, New York. It employs about 75,000 people and sells medicines in more than 180 countries. Its history includes Terramycin, Lipitor (via Warner-Lambert), Viagra, Prevnar (via Wyeth) and the Comirnaty COVID-19 vaccine developed with BioNTech. The company is headquartered in New York City, New York. Pfizer was founded in 1849 in Brooklyn, New York City, by German immigrant cousins Charles Pfizer and Charles F. Erhart as a fine-chemicals business, expanding over 175 years into a global biopharmaceutical giant discovering penicillin, Lipitor, Viagra, and the landmark COVID-19 vaccine Comirnaty.

Merck & Co., Inc. and Pfizer Inc. pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Merck & Co., Inc. and Pfizer Inc..

Merck & Co., Inc. business model: Merck makes money by selling patent-protected prescription medicines, vaccines and animal health products. The Pharmaceutical segment produced about $58.1 billion of 2025 sales, led by Keytruda/Keytruda Qlex ($31.7 billion), Gardasil ($5.2 billion), Januvia/Janumet ($2.5 billion) and Winrevair ($1.4 billion). Animal Health added about $6.4 billion from companion-animal products such as Bravecto and livestock vaccines. Sales go mainly to wholesalers, hospitals, governments and immunization programs, and the U.S. accounts for more than half of revenue. Merck reinvests heavily, spending $15.8 billion on R&D in 2025, and buys late-stage assets (Verona Pharma, Cidara, Terns) to replace revenue before patents expire.

Pfizer Inc. business model: Pfizer makes money by selling patented prescription medicines and vaccines to wholesalers, hospitals, governments and pharmacies, with the United States as its largest market. Revenue is concentrated in large franchises such as Eliquis (co-commercialized with Bristol Myers Squibb), the Prevnar pneumococcal vaccines, the Vyndaqel tafamidis family, Ibrance, Xtandi and the Seagen antibody-drug conjugates. Pfizer funds internal R&D but sources much of its pipeline externally through acquisitions (Seagen, Metsera) and licensing deals (Innovent, 3SBio), then uses its regulatory, manufacturing and commercial scale to launch products globally during their exclusivity window.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Merck & Co., Inc. stack up against those of Pfizer Inc..

Merck & Co., Inc. competitive advantage: Merck's edge rests on the scale of its Keytruda clinical program, with more than 40 approved indications, plus a large biologics manufacturing network and a vaccine franchise built over decades. Each new Keytruda approval reuses the same oncology sales relationships and safety data, which lowers the cost of every additional indication. The September 2025 approval of subcutaneous Keytruda Qlex, which sold $463 million in Q2 2026, gives Merck a newer formulation to move patients onto before IV biosimilars arrive. Animal Health adds a steadier, less patent-driven profit stream.

Pfizer Inc. competitive advantage: Pfizer's advantage is scale in late-stage development, regulatory filings, manufacturing and commercialization. The BioNTech partnership showed it: BioNTech supplied the mRNA science, while Pfizer ran the global Phase 3 trial with more than 40,000 participants, built ultra-cold distribution and manufactured billions of Comirnaty doses. That capability also makes Pfizer a natural buyer or partner for smaller biotechs that lack global reach.

Future prospects matter as much as current results. The growth strategies below explain how Merck & Co., Inc. and Pfizer Inc. each plan to expand from here.

Merck & Co., Inc. growth strategy: Merck's strategy is to use Keytruda cash flow to build a broader portfolio before 2028. It moved patients toward subcutaneous Keytruda Qlex (FDA-approved September 19, 2025), expanded Keytruda into earlier-stage cancers, and bought late-stage or commercial assets: Verona Pharma for about $10 billion (completed October 2025, adding COPD drug Ohtuvayre), Cidara Therapeutics for about $9.2 billion (completed January 2026, adding influenza preventive CD388), and Terns Pharmaceuticals for about $6.7 billion (completed in Q2 2026, adding CML candidate MK-4208). Earlier deals include Acceleron ($11.5 billion, 2021), Prometheus Biosciences ($10.8 billion, 2023) and the Daiichi Sankyo ADC collaboration (up to $22 billion, 2023).

Pfizer Inc. growth strategy: Pfizer's growth plan has three parts. Oncology: the $43 billion Seagen deal (closed December 2023) added Padcev, Adcetris, Tukysa and Tivdak, and Pfizer licensed 3SBio's PD-1xVEGF bispecific in 2025 and signed a 12-program cancer collaboration with Innovent Biologics in May 2026 ($650 million upfront, up to $10.5 billion total). Obesity: Pfizer acquired Metsera in November 2025 for about $10 billion including contingent value rights, after a bidding contest with Novo Nordisk. Cost: a multi-year cost realignment and manufacturing optimization program funds R&D and protects margins.

A closer look at the financial trajectory of Merck & Co., Inc. and Pfizer Inc. rounds out the comparison.

Merck & Co., Inc.: Merck reported $65.0 billion in 2025 sales, up 1% from $64.2 billion in 2024, and $18.3 billion in net income attributable to Merck. Keytruda/Keytruda Qlex grew 7% to $31.7 billion, offsetting a 39% Gardasil decline. Momentum continued in 2026: Q2 2026 sales rose 5% to $16.6 billion, with Keytruda at $8.4 billion (including $463 million from Keytruda Qlex), Winrevair up 75% to $588 million and Animal Health up 8% to $1.8 billion. A $2.31-per-share charge for the Terns acquisition produced a Q2 GAAP net loss of $1.3 billion. In August 2026 Merck raised its full-year 2026 sales outlook to $66.3 billion to $67.3 billion, with non-GAAP EPS of $2.66 to $2.76 after Terns-related charges. Merck & Co. commands a robust market valuation frequently over $300 billion, driven heavily by its blockbuster oncology drug Keytruda.

Pfizer Inc.: Pfizer revenue rose from $41.7 billion in 2020 to $81.3 billion in 2021 and $101.2 billion in 2022 on Comirnaty and Paxlovid, then fell to $59.6 billion in 2023 as COVID demand collapsed. It recovered to $63.6 billion in 2024 and was $62.6 billion in 2025, with net income of $7.8 billion. In Q2 2026 revenue was $15.0 billion, up 1% operationally, or 5% excluding COVID products, and Pfizer raised the midpoint of its 2026 revenue guidance to $60.5 billion to $62.5 billion with adjusted EPS guidance of $2.80 to $3.00. The roughly $31 billion of debt raised for Seagen in 2023 and an ongoing cost-reduction program shape capital allocation alongside a dividend yield near 6%. Pfizer ranks among the largest pharmaceutical companies in the world, carrying a market valuation typically exceeding $150 billion.